免疫毒素
免疫系统
癌症研究
免疫学
癌症
抗体
免疫疗法
医学
生物
单克隆抗体
内科学
作者
Michael Flynn,John A. Hartley
摘要
Summary CD 25 (also termed IL 2 RA ) forms one component of the high‐affinity heterotrimeric interleukin 2 ( IL 2) receptor on activated T cells. Its affinity for IL 2 and cellular function are tightly regulated and vary in different cell types. The high frequency of CD 25 on the surface of many different haematological tumour cells is now well established and, apart from its prognostic significance, CD 25 may be present on leukaemic stem cells and enable oncogenic signalling pathways in leukaemic cells. Additionally, high CD 25 expression in activated circulating immune cells and Tregs is a factor that has already been exploited by IL 2 immunotherapies for treatment of tumours and autoimmune disease. The relative clinical safety and efficacy of administering anti‐ CD 25 radioimmunoconjugates and immunotoxins in various haematological tumour indications has been established and clinical trials of a novel CD 25‐directed antibody drug conjugate are underway.
科研通智能强力驱动
Strongly Powered by AbleSci AI